Brilliant Acquisition 10-K 13 Jan 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Oct. 31, 2013	Jan. 09, 2014	Apr. 30, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'BIO REFERENCE LABORATORIES INC	'	'
Entity Central Index Key	'0000792641	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Oct-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--10-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$623,072,381
Entity Common Stock, Shares Outstanding	'	27,695,213	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Oct. 31, 2013	Oct. 31, 2012
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and Cash Equivalents	$17,952	$25,143
Accounts Receivable - Net	206,261	153,247
Inventory	19,095	14,902
Other Current Assets	9,416	5,373
Deferred Tax Assets	42,154	24,912
TOTAL CURRENT ASSETS	294,878	223,577
PROPERTY AND EQUIPMENT - AT COST	133,599	102,701
LESS: Accumulated Depreciation	-67,950	-52,261
PROPERTY AND EQUIPMENT - NET	65,649	50,440
OTHER ASSETS:	'	'
Investments	5,237	4,977
Deposits	1,017	956
Goodwill - Net	35,185	23,408
Intangible Assets - Net	16,320	6,323
Other Assets	1,165	866
Deferred Tax Assets	2,077	2,278
TOTAL OTHER ASSETS	61,001	38,808
TOTAL ASSETS	421,528	312,825
CURRENT LIABILITIES:	'	'
Accounts Payable	61,614	41,288
Accrued Salaries and Commissions Payable	19,601	16,490
Accrued Taxes and Expenses	18,292	9,753
Other Short Term Acquisition Payable	2,438	'
Revolving Note Payable - Bank	26,139	0
Current Maturities of Long-Term Debt	493	464
Capital Lease Obligations - Short-Term Portion	5,185	3,957
TOTAL CURRENT LIABILITIES	133,762	71,952
LONG-TERM LIABILITIES:	'	'
Capital Lease Obligations - Long-Term Portion	10,712	9,463
Long Term Debt - Net of Current Portion	3,670	4,163
Other Long Term Acquisition Payable	1,789	'
TOTAL LONG-TERM LIABILITIES	16,171	13,626
SHAREHOLDERS' EQUITY:	'	'
Preferred Stock $.10 Par Value; Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued	'	'
Common Stock, $.01 Par Value; Authorized 35,000,000 shares: Issued and Outstanding 27,683,213 and 27,707,382 at October 31, 2013 and at October 31, 2012, respectively	277	277
Additional Paid-In Capital	39,430	40,907
Retained Earnings	231,888	186,063
TOTAL SHAREHOLDERS' EQUITY	271,595	227,247
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$421,528	$312,825

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Preferred Stock, Par Value (in dollars per share)	$0.10	$0.10
Preferred Stock, Authorized shares, including Series A Junior Preferred Stock	1,666,667	1,666,667
Preferred Stock, Issued shares	0	0
Common Stock, Par Value (in dollars per share)	$0.01	$0.01
Common Stock, Authorized shares	35,000,000	35,000,000
Common Stock, Issued shares	27,683,213	27,707,382
Common Stock, Outstanding shares	27,683,213	27,707,382
Series A Junior Preferred Stock	'	'
Preferred Stock, Authorized shares	3,000	3,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
CONSOLIDATED STATEMENTS OF OPERATIONS	'	'	'
NET REVENUES:	$715,354	$614,255	$522,081
COST OF SERVICES:	'	'	'
Depreciation and Amortization	15,598	13,101	11,036
Employee Related Expenses	173,137	146,292	126,354
Reagents and Lab Supplies	135,486	121,446	100,569
Other Cost of Services	68,594	56,805	49,894
TOTAL COST OF SERVICES	392,815	337,644	287,853
GROSS PROFIT ON REVENUES	322,539	276,611	234,228
General and Administrative Expenses:	'	'	'
Depreciation and Amortization	4,141	3,562	3,969
Other General and Administrative Expenses	177,508	154,928	131,967
Bad Debt Expense	58,917	41,990	38,518
TOTAL GENERAL AND ADMIN. EXPENSES	240,566	200,480	174,454
OPERATING INCOME	81,973	76,131	59,774
OTHER (INCOME) EXPENSES:	'	'	'
Interest Expense	1,606	1,455	1,747
Other (Income) Expense	-612	323	-6,656
Interest Income	-118	-163	-163
TOTAL OTHER EXPENSES - NET	876	1,615	-5,072
INCOME BEFORE INCOME TAXES	81,097	74,516	64,846
Provision for Income Taxes	35,272	32,360	28,487
NET INCOME	$45,825	$42,156	$36,359
NET INCOME PER SHARE - BASIC: (in dollars per share)	$1.65	$1.52	$1.30
WEIGHTED AVERAGE NUMBER OF SHARES - BASIC: (in shares)	27,690,677	27,742,257	27,971,100
NET INCOME PER SHARE - DILUTED: (in dollars per share)	$1.65	$1.51	$1.29
WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED: (in shares)	27,851,720	27,920,920	28,207,358

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings
In Thousands, except Share data, unless otherwise specified
Balance at Oct. 31, 2010	$152,388	$278	$44,562	$107,548
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Exercise of Options - Employees	498	1	497	'
Exercise of Options - Employees (in shares)	'	79,600	'	'
Stock Based Compensation	40	'	40	'
Stock Issued for Acquisition	482	'	482	'
Stock Issued for Acquisition (in shares)	'	23,096	'	'
Net Income	36,359	'	'	36,359
Balance at Oct. 31, 2011	189,767	279	45,581	143,907
Balance (in shares) at Oct. 31, 2011	'	27,949,900	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Exercise of Options - Employees	227	1	226	'
Exercise of Options - Employees (in shares)	'	31,500	'	'
Stock Based Compensation	290	'	290	'
Stock Based Compensation (in shares)	'	11,432	'	'
Net Income	42,156	'	'	42,156
Common Stock Repurchased and Canceled	-5,193	-3	-5,190	'
Common Stock Repurchased and Canceled (in shares)	-285,450	-285,450	'	'
Balance at Oct. 31, 2012	227,247	277	40,907	186,063
Balance (in shares) at Oct. 31, 2012	'	27,707,382	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Exercise of Options - Employees	263	'	263	'
Exercise of Options - Employees (in shares)	'	46,000	'	'
Stock Based Compensation	290	'	290	'
Stock Based Compensation (in shares)	'	11,431	'	'
Net Income	45,825	'	'	45,825
Common Stock Repurchased and Canceled	-2,030	'	-2,030	'
Common Stock Repurchased and Canceled (in shares)	-81,600	-81,600	'	'
Balance at Oct. 31, 2013	$271,595	$277	$39,430	$231,888
Balance (in shares) at Oct. 31, 2013	'	27,683,213	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
OPERATING ACTIVITIES:	'	'	'
Net Income	$45,825	$42,156	$36,359
Adjustments to Reconcile Net Income to Cash Provided by Operating Activities:	'	'	'
Depreciation and Amortization	19,739	16,663	15,005
Deferred Income Taxes (Benefit)	-17,041	-3,638	-5,911
Stock - Based Compensation Expense	290	290	40
Loss on Disposal of Property and Equipment	1,408	537	1,680
Undistributed Equity Method (Income) Loss	450	323	'
(Increase) Decrease in:	'	'	'
Accounts Receivable	-91,002	-11,240	-29,254
Provision for Doubtful Accounts	37,988	6,053	10,316
Inventory	-4,193	-5,211	-3,498
Other Current Assets	-4,043	-916	-1,637
Other Assets	-299	-141	798
Deposits	-61	-74	507
Increase (Decrease) in:	'	'	'
Accounts Payable and Accrued Liabilities	28,601	8,296	6,541
NET CASH - OPERATING ACTIVITIES	17,662	53,098	30,946
INVESTING ACTIVITIES:	'	'	'
Business Acquisitions Related Costs	-19,013	-5,675	-1,425
Acquisition of Equipment and Leasehold Improvements	-25,100	-15,715	-14,117
NET CASH - INVESTING ACTIVITIES	-44,113	-21,390	-15,542
FINANCING ACTIVITIES:	'	'	'
Payments of Long-Term Debt	-464	-1,270	-1,178
Payments of Capital Lease Obligations	-4,648	-3,710	-2,968
Increase (Decrease) in Revolving Note Payable	26,139	-18,632	-7,522
Proceeds from Exercise of Options	263	227	498
Common Stock Repurchased	-2,030	-5,193	'
NET CASH - FINANCING ACTIVITIES	19,260	-28,578	-11,170
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-7,191	3,130	4,234
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS	25,143	22,013	17,779
CASH AND CASH EQUIVALENTS AT END OF PERIODS	17,952	25,143	22,013
Cash paid during the period for:	'	'	'
Interest	1,503	1,547	1,754
Income Taxes	44,312	36,697	32,773
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:	'	'	'
Write-off of property and equipment	4,464	2,508	5,944
Equipment with an initial cost	'	'	4,558
Purchase of new equipment	'	'	5,408
Capital Leases	$7,125	$7,777	$5,444

Organization_and_Business

Organization and Business	12 Months Ended
	Oct. 31, 2013
Organization and Business	'
Organization and Business	'
	[1] Organization and Business
	Bio-Reference Laboratories, Inc. [“Bio-Reference”, “BRLI”, or the “Company”] was incorporated on December 24, 1981.  Bio-Reference is principally engaged in providing laboratory testing services, primarily to customers in the greater New York metropolitan area as well as to customers in a number of other states.  Bio-Reference offers a comprehensive list of chemical diagnostic tests including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology (including drug screening), pap smears, tissue pathology (biopsies) and other tissue analysis.  We perform cancer cytogenetic testing at our leased facilities in at our main processing facility in Elmwood Park, Smithtown, NY, Clarksburg, MD and Milford, MA and genetic testing at our GeneDx leased facility in Gaithersburg, MD, as well as at our Elmwood Park facility.  We perform cytology testing in Frederick, MD, Milford, MA, Columbus, OH, Houston, TX and at our Elmwood Park facility.  Bio-Reference markets its laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.
	The Company’s laboratory testing business currently represents its one reportable business segment. The laboratory testing business accounts for over 98% of consolidated assets, net revenues and net income in each of the three years ended October 31, 2013.  All other operating segments include the Company’s non-clinical laboratory testing businesses and consist of our clinical knowledge management service through our PSIMedica business unit and a web-based connectivity portal solution for laboratories and physicians through its Care Evolve subsidiary.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2013
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	[2] Summary of Significant Accounting Policies
	Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.
	Cash and Cash Equivalents - Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased.  The Company had $17,952 and $25,143 in cash and cash equivalents at October 31, 2013 and 2012, respectively.
	Inventory - Inventory is stated at the lower of cost [determined on a first-in, first-out basis] or market.  Inventory consists of purchased laboratory supplies, which is used in our various testing laboratories.
	Property and Equipment - Property and equipment are carried at cost.  Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets, which generally range from 2 to 15 years.  Leasehold improvements are amortized over the life of the lease or improvement, which is typically five years.
	The statements of operations reflect depreciation expense related to property and equipment of $18,745, $16,082 and $13,684 for the years ended October 31, 2013, 2012 and 2011, respectively.
	On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in general and administrative expenses.  Repairs and maintenance are charged to expense when incurred.
	Goodwill - Effective November 1, 2011, the Company adopted revised Financial Accounting Standards Board (“FASB”)  rules promulgated under Accounting Standards Update (“ASU”) No. 2011-08 issued on September 15, 2011, Intangibles—Goodwill and Other (Topic 350) Testing Goodwill for Impairment. Under these simplified goodwill impairment testing rules the Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.  Under ASU No. 2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit’s carrying value is greater than its fair value based on an assessment of events and circumstances. The “more likely than not” threshold is when there is a likelihood of more than 50% that a reporting unit’s carrying value is greater than its fair value.  No impairment loss was recognized in the years ended October 31, 2013, 2012 and 2011.
	The balance sheet reflects prior Goodwill accumulated amortization of $2,401 as of October 31, 2013 and 2012, respectively.
	Other Intangible Assets - Intangible assets are amortized using the straight-line method.  The estimated useful life of costs capitalized is evaluated for each specific project when completed, at which time such costs begin to be amortized. The statements of operations reflect amortization expense related to intangible assets of $994, $581, and $1,322 for the years ended October 31, 2013, 2012 and 2011, respectively.  The balance sheet reflects accumulated amortization of $8,846, and $7,852 as of October 31, 2013, and 2012, respectively. During the 2013 and 2012 fiscal years, the Company did not write off any intangible assets.
	New Accounting pronouncements
	Certain prior year amounts have been reclassified to conform to the current year presentation. The Company adopted Accounting Standard Update (“ASU”) No. 2011-7: Health Care Entities (Topic 954) — Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities commencing with the current fiscal year, the first year such standard is required for the Company. The adoption of this update did not have a material impact on the Company’s financial statements.
	Although this update does not have a material impact on the Company’s financial statements as a whole, it requires that we adjust our presentation of our statement of operations along with prior periods presented in this report to maintain comparability. As the result of this change in presentation, our “Net Revenues”, “Gross Profit on Revenues” and our “General and Administrative Expenses” would change while our “Operating Income”, “Net Income” and “Earnings per Share” will remain the same. The presentation is adjusted for a portion of our “Bad Debt Expense” that is now reported in our Net Revenues as required under ASU No. 2011-7.
	Accounting for Revenue
	Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.
	Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.  The majority of services provided by Bio-Reference Laboratories, Inc. (“BRLI”) are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburses BRLI directly.  In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends This process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed. The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.
		($)
		Year Ended
		October 31,
		2013		2012		2011
	Gross Service Revenues	3,524,108		3,052,431		2,482,349
	Contractual Adjustments and Discounts:
	Medicare/Medicaid Portion	354,638		320,697		293,874
	All Other Third Party Payors*	2,393,872		2,070,073		1,629,833
	Total Contractual Adjustments and Discounts	2,748,510		2,390,770		1,923,707
	Service Revenues Net of Contractual Adjustments and Discounts	775,598		661,661		558,642
	Patient Service Revenue Provision for Bad Debts**	60,244		47,406		36,561
	Net Revenues	715,354		614,255		522,081
	Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue.	79.7	%	79.9	%	79	%
	* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.
	** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.
	When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience. The remaining bad debt expense is presented as part of operating expenses. The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.  BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.
	Accounting for Contractual Credits and Doubtful Accounts
	It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:
		($)
		October 31,		October 31,
		2013		2012
	Contractual Credits/Discounts	342,297		267,921
	Doubtful Accounts	89,261		51,274
	Total Allowance	431,558		319,195
	Current Income Taxes — The Company recognizes interest and penalties on settlement of tax liabilities in its income from operations.  For the fiscal years 2011 through 2013, no material amounts for interest and penalties have been recorded.
	Deferred Income Taxes - Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.
	The Company adopted GAAP guidance with respect to uncertain tax positions when it became effective.  Under these rules the Company may recognize the tax benefit from an uncertain tax position only if it meets the more-likely-than-not criteria (over 50% likelihood) of being realized on an examination by taxing authorities.  For the years ended October 31, 2011 through October 31, 2013 the Company had no material uncertain tax positions to report.
	Earnings Per Share - Basic earnings per share [“EPS”] reflects the amount of income attributable to each share of common stock based on average common shares outstanding during the period.  Diluted EPS reflects Basic EPS while giving effect to all potential dilutive common shares that were outstanding during the period, such as common shares that could result from the exercise or conversion of securities into common stock.  The computation of Diluted EPS is calculated by using the treasury stock method, which assumes that any proceeds obtained from the exercise of such dilutive securities would be used to purchase common stock at the average market price of the common stock during the period.  This reduces the gross number of dilutive shares by the number of shares purchasable from the proceeds of the securities assumed to be exercised.  Securities whose conversion would have an anti-dilutive effect on EPS are not assumed converted.  Securities that could potentially dilute earnings in the future are disclosed in Note 10.
	Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets — The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.  The Company reviews the recoverability of its long-lived assets on an annual basis.  Evaluation of possible impairment is based on the Company’s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.  No impairment loss was recognized in the fiscal years ended October 31, 2013, 2012 and 2011.
	Advertising Costs -Advertising costs are expensed when incurred.  Advertising costs amounted to approximately $3,200, $2,366 and $2,026 for the years ended October 31, 2013, 2012 and 2011, respectively.
	Other Income — During the year the Company recorded a loss of $450on its investment in IncellDx.  The loss represents the Company’s share of IncellDX undistributed net loss under the equity method of accounting.  During the year ended October 31, 2013 the Company received a refund of $1,062 for its New York State clinical laboratory inspection fee that was included in other income.
	Subsequent Events — The management considered subsequent events through the date the financial statements are issued as defined in FASB Codification 855-10-50.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Oct. 31, 2013
Property and Equipment	'
Property and Equipment	'
	[3] Property and Equipment - Property and equipment - at cost is summarized as follows:
		October 31
		2013		2012
	Medical Equipment	$	65,762	$	50,338
	Leasehold Improvements	27,974		19,768
	Furniture, Fixtures and Office & Computer Equipment	21,621		16,503
	Automobiles and Aircraft	18,242		16,092
	Sub Totals	133,599		102,701
	Less Accumulated Depreciation	67,950		52,261
	Totals — Net of Accumulated Depreciation	$	65,649	$	50,440

Intangible_Assets

Intangible Assets	12 Months Ended
	Oct. 31, 2013
Intangible Assets	'
Intangible Assets	'
	[4] Intangible Assets
	Intangible assets are summarized as follows:
	October 31, 2013
		Weighted-Average				Accumulated		Net of
								Accumulated
	Intangible Asset	Amortization Period		Cost		Amortization		Amortization
	Customer Lists	20		$	8,739	$	2,879	$	5,860
	Covenants Not-to-Compete	3		11,131		4,560		6,571
	Patents and Licenses	17		5,297		1,408		3,889
	Totals			$	25,166	$	8,847	$	16,320
	October 31, 2012
		Weighted-Average				Accumulated		Net of
								Accumulated
	Intangible Asset	Amortization Period		Cost		Amortization		Amortization
	Customer Lists	20		$	4,573	$	2,537	$	2,036
	Covenants Not-to-Compete	5		4,305		4,257		48
	Patents and Licenses	17		5,297		1,058		4,239
	Totals			$	14,175	$	7,852	$	6,323
	The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of October 31, 2013 is as follows:
	October 31,
	2014	$	1,917
	2015	1,852
	2016	1,540
	2017	1,063
	2018	946
	Thereafter	9,002
	Total	$	16,320

Revolving_Note_Payable_Bank

Revolving Note Payable - Bank	12 Months Ended
	Oct. 31, 2013
Revolving Note Payable - Bank	'
Revolving Note Payable - Bank	'
	[5] Revolving Note Payable - Bank
	In October 2011, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A.  The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) $45,000 or (ii) 50% of the Company’s qualified accounts receivable [as defined in the agreement].  The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank’s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.  The additional interest percentage charge on bank’s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.  At October 31, 2013, the Company had elected to have all of the total advances outstanding to be subject to the bank’s base rate of interest of 3.50%.  The credit line is collateralized by substantially all of the Company’s assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent, thereafter.  The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures, fixed charge coverage, and the prohibition of the payment by the Company of cash dividends. As of October 31, 2013 and October 31, 2012, the Company utilized $26,139 and $0 of the credit line, respectively.

LongTerm_Debt_Bank

Long-Term Debt - Bank	12 Months Ended
	Oct. 31, 2013
Long-Term Debt - Bank	'
Long-Term Debt - Bank	'
	[6] Long-Term Debt - Bank
	Effective as of October 31, 2007, we executed a fifth amendment to the Loan Agreement formalizing the repayment terms of the $5 million term loan from PNC Bank used by our wholly-owned GeneDX (formerly, BRLI No. 2 Acquisition Corp.) subsidiary to fund the $5 million acquisition cash payment in connection with its purchase of the operating assets of GeneDx, Inc. The term loan is evidenced by a secured promissory note payable over a six year term in equal monthly principal payments of approximately $69, plus interest at an annual rate of 6.85%. The note was paid off on October 31, 2012.
	In December 2010, the Company issued a seven year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.  The note is payable in eighty-four equal monthly installments commencing on January 29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of December 29, 2017.  The balance on this note as of October 31, 2013 is approximately $4,163.
	Principal repayment for each of the five succeeding fiscal years and thereafter as of October 31, 2013 is as follows:
	Year Ended
	October 31,
	2014	493
	2015	518
	2016	551
	2017	585
	2018	2,016
	Thereafter	—
	Totals	$	4,163

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Oct. 31, 2013
Related Party Transactions	'
Related Party Transactions	'
	[7] Related Party Transactions [Not in Thousands]
	There were no material related party transactions during fiscal 2013 and fiscal 2012.

Income_Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2013
Income Taxes	'
Income Taxes	'
	[8] Income Taxes
	The reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the Company’s effective income tax rate is as follows:
		October 31
		2013		2012		2011
	U.S. Federal Statutory Rate	35	%	35	%	35	%
	State and Local Taxes, Net of U.S. Federal Tax Benefit	11.2	%	8.87	%	9.87	%
	Permanent differences and Other	(2.78	)%	(0.44	)%	(0.94	)%
	Actual Rate	43.42	%	43.43	%	43.93	%
	The provision for income taxes shown in the consolidated statements of operations consists of the following:
		October 31
		2013			2012			2011
	Current:
	Federal	$	38,295		$	25,794		$	24,573
	State & Local	14,018			10,203			9,825
	Deferred:
	Federal	(10,803		)	(2,183		)	(4,223		)
	State and Local	(6,238		)	(1,454		)	(1,688		)
	Total Provision for Income Taxes	$	35,272		$	32,360		$	28,487
	At October 31, 2013 and 2012, the Company had a net deferred tax asset of approximately $44,231 and $27,190, respectively.  The deferred taxes primarily relate to timing differences associated with the deductibility of depreciation and amortization, bad debts and certain accrued expenses and deferred costs.  For fiscal years ended October 31 2011 through October 31, 2013, the Company had no material net operating loss carry-forwards available to reduce current year taxable income.
		October 31,
		2013			2012
	Deferred Tax Asset:
	Bad Debt Allowance	$	39,275		$	22,560
	Depreciation and amortization	1,815			1,963
	Accrued Expenses	3,141			2,667
	Deferred Tax Asset - Net	44,231			27,190
	Current Deferred Tax Asset - Net	42,154			24,912
	Long Term Deferred Tax Asset - Net	2,077			2,278
	Deferred Tax Asset — Net	44,231			$	27,190
	During fiscal year ended October 31, 2013 the Company recorded a net deferred tax benefit of $17,041.  This reflects a net benefit of approximately $16,715 in allowance for bad debts, a liability of approximately $281 from depreciation and amortization timing differences, and a benefit of approximately $607 in certain accrued expenses. Although realization is not assured and dependent upon things such as generating sufficient taxable income in future periods, management, through sufficient positive evidence,  believes it is more likely than not that all of the deferred tax asset will be realized. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income or changes in the accrued expenses during the future periods are reduced.
	At October 31, 2013, fiscal 2010 through 2013 are subject to examination by US federal and state tax authorities.  Through the issuance of these financial statements the outcome of all of these examinations has not been determined.

Capital_Transactions

Capital Transactions	12 Months Ended
	Oct. 31, 2013
Capital Transactions	'
Capital Transactions	'
	[9] Capital Transactions
	[A] Preferred Stock and Common Stock - The Company is authorized to issue an aggregate of 1,666,667 shares of preferred stock, $.10 par value.  None was outstanding as of October 31, 2013 and October 31, 2012.
	Holders of the Company’s Common Stock are entitled to one vote per share on matters submitted for shareholder vote.  Holders are also entitled to receive dividends ratably, if declared.  In the event of dissolution or liquidation, holders are entitled to share ratably in all assets remaining after payment of liabilities.
	On November 11, 2011, the Company announced that its board of directors has approved a Stock Repurchase Program authorizing the repurchase of up to 1,000,000 shares of its Common Stock in the over-the-counter market at prevailing market prices over the period ending October 31, 2012.  During the year ended October 31, 2012 the Company repurchased 285,450 shares at a cost of $5,193.  On December 6, 2012, the Company announced that its board of directors has approved a new Stock Repurchase Program authorizing the buyback of up to 714,550 shares of its Common Stock in the over-the-counter market at prevailing market prices through October 31, 2013.  As of October 31, 2013, the Company repurchased 81,600 shares at a cost of $2,030.  Subsequent to our year end, on December 19, 2013 the Company announced that its board of directors has approved a new Stock Repurchase Program authorizing the buyback of up to 2,000,000 shares of its Common Stock in the over-the-counter market at prevailing market prices through October 31, 2015.
	[B] Equity Transactions for Services — For the fiscal years ended in 2013, 2012 and 2011, the Company issued 11,431, 11,432 and 11,432 shares of the Company’s common stock for employment or consulting services [See Note 11 for common stock options issued for employee and consulting services].

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Oct. 31, 2013
Earnings Per Share	'
Earnings Per Share	'
	[10] Earnings Per Share
	The computation of basic and diluted net earnings per common share is as follows [in thousands, except per share data rounded]:
		For Years Ended October 31,
		2013		2012		2011
	Income Available to Common Stockholders	$	45,825	$	42,156	$	36,359
	Weighted Average Common Shares Outstanding	27,691		27,742		27,971
	Effect of Dilutive Securities:
	Warrants/Options	161		179		236
	Weighted Average Diluted Common Shares Outstanding	27,852		27,921		28,207
	Net Income Per Share - Basic	$	1.65	$	1.52	$	1.3
	Net Income Per Share - Diluted	$	1.65	$	1.51	$	1.29

Stock_Options_and_Warrants

Stock Options and Warrants	12 Months Ended
	Oct. 31, 2013
Stock Options and Warrants	'
Stock Options and Warrants	'
	[11] Stock Options and Warrants
	Employee Incentive Stock Options - In June 2003, the Board of Directors adopted, and in July 2003, the stockholders approved, the 2003 Employee Incentive Stock Option Plan [the “2003 Plan”].  The 2003 Plan authorizes the grant of stock options, which may be designated as  incentive stock options, to purchase up to a maximum aggregate 1,600,000 shares of Company common stock.  The 2003 Plan provides that the exercise price of an option granted there under shall not be less than the fair market value of the Common Stock on the date the option is granted.  However, in the event an option is granted under the 2003 Plan to a holder of 10% or more of the Company’s outstanding Common Stock, the exercise price must be at least 110% of such fair market value.  Under the 2003 Plan, options must be granted before the June 2, 2013 Termination Date.  No option may have a term longer than ten years (limited to five years in the case of an option granted to a 10% or greater stockholder of the Company).  The aggregate fair market value of the Company’s Common Stock with respect to which options are exercisable for the first time by a grantee under all of the Company’s Stock Option Plans during any calendar year cannot exceed $100.  Options granted under the 2003 Plan are non-transferable and must be exercised by an optionee, if at all, while employed by the Company or a subsidiary or within three months after termination of such optionee’s employment due to retirement, or within one year of such termination if due to disability or death.  The Board (or a Stock Option Committee, if designated), may, in its sole discretion, cause the Company to lend money to or guaranty any obligation of an employee for the purpose of enabling such employee to exercise an option granted under the 2003 Plan provided that such loan or obligation cannot exceed fifty percent (50%) of the exercise price of such option. In fiscal year ended October 31, 2013, 2012 and 2011, -0-, -0- and -0- options were granted under the Plan, respectively. A total of 4,000, 23,500 and 40,000 incentive stock options issued under the 2003 Plan were exercised in fiscal years ended in October 31, 2013, 2012 and 2011, respectively.  A total of 6,000, 13,000 and -0- options were cancelled in fiscal years ended October 31, 2013, 2012 and 2011.
	In August 2000, the Company adopted, and on December 15, 2000, the stockholders approved, the 2000 Employee Incentive Stock Option Plan [“2000 Plan”]. The 2000 Plan provided for the granting of stock options, which may have been designated as incentive stock options, to purchase an aggregate of 1,600,000 shares of the Company’s common stock at a price not less than 100% of the fair market value per share of the common stock at the date of grant.  However, in the event an option was granted under the 2000 Plan to a holder of 10% or more of the Company’s outstanding common stock, the exercise price must have been at least 110% of fair market value at the date of grant.  Employees of the Company or its subsidiary, as determined, were eligible for the 2000 Plan.  The term of the options could not exceed ten years from the date of grant.  In fiscal years ended October 31, 2013, 2012 and 2011, no options were granted under the Plan. A total of 44,000, 8,000 and 39,600 incentive stock options issued under the 2000 Plan were exercised in fiscal years ended in October 31, 2013, 2012 and 2011, respectively. A total of 2,000, -0-, and -0- options were cancelled in fiscal years ended October 31, 2013, 2012 and 2011, respectively.  Options issued under the 2000 Plan must have been granted before the August 2010 termination date.
	The following is a summary of Employee Incentive Stock Option Plan transactions:
		2003 Plan
		Shares Under Options		Weighted Average
		[In Thousands]		Exercise Price Per Share
	Outstanding at October 31, 2010*	335		9.66
	Granted	—		—
	Expired	—		—
	Exercised	(40	)	8.67
	Outstanding at October 31, 2011*	295		9.8
	Granted	—		—
	Expired	(13	)	9.13
	Exercised	(23	)	8.52
	Outstanding at October 31, 2012*	259		$	9.95
	Granted	—		—
	Expired	(6	)	8.64
	Exercised	(4	)	7.25
	Outstanding at October 31, 2013*	249		10.02
	*Eligible for exercise at October 31, 2010 were 310 at a weighted average exercise price per share of $9.66
	*Eligible for exercise at October 31, 2011 were 275 at a weighted average exercise price per share of $9.80
	*Eligible for exercise at October 31, 2012 were 244 at a weighted average exercise price per share of $9.95
	*Eligible for exercise at October 31, 2013 were 239 at a weighted average exercise price per share of $9.97
		2000 Plan
		Shares Under		Weighted
		Options		Average
		[In Thousands]		Exercise Price
				Per Share
	Outstanding and Eligible for Exercise at October 31, 2010	100		4.64
	Granted	—		—
	Expired	—		—
	Exercised	(40	)	3.82
	Outstanding and Eligible for Exercise at October 31, 2011	60		5.19
	Granted	—		—
	Expired	—		—
	Exercised	(8	)	3.39
	Outstanding and Eligible for Exercise at October 31, 2012	52		$	5.47
	Granted	—		—
	Expired	(2	)	3.6
	Exercised	(44	)	5.25
	Outstanding and Eligible for Exercise at October 31, 2013
		6		7.67
	Summary of outstanding options:
							Weighted Average			Exercisable
							Shares	Remaining	Exercise	Shares	Exercise
	Exercise Price Range						Outstanding	Life	Price	Outstanding	Price
	$6.11	to		$6.11		Per Share	6	0.75	6.11	6	6.11
	$7.41	to		$7.67		Per Share	62	1.09	7.48	62	7.48
	$9.13	to		$9.13		Per Share	147	1	9.13	147	9.13
	$17.50	to		$17.50		Per Share	40	4.08	17.5	30	17.5
							255			245
	Compensation cost recognized for the years ended October 31, 2013, October 31, 2012 and October 31, 2011 was $40 for each one of the years, with a related tax benefit of $-0- with respect to these options.

Employment_Contracts_and_Consu

Employment Contracts and Consulting Agreements	12 Months Ended
	Oct. 31, 2013
Employment Contracts and Consulting Agreements	'
Employment Contracts and Consulting Agreements	'
	[12] Employment Contracts and Consulting Agreements
	The Company has multiple employment contracts with its key executives with expiration dates ranging from October 31, 2015 through October 31, 2018.  At October 31, 2013, the approximate aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases, is as follows:
	October 31	Employees and
		Consultants
	2014	$	5,169
	2015	3,873
	2016	3,657
	2017	2,918
	2018	1,243
	Thereafter	—
	Total	$	16,860
	Some of these agreements provide bonuses and commissions based on a percentage of collected revenues ranging from 1% to 10% on accounts referred by or serviced by the employee or consultant.
	In addition to the above, in fiscal 2013 the Company has entered into seventy at — will employment and consulting agreements which together with prior at — will agreements provide for annual aggregate minimum commitments of approximately $33,555 which have no termination dates.

Capitalized_Lease_Obligations

Capitalized Lease Obligations	12 Months Ended
	Oct. 31, 2013
Capitalized Lease Obligations	'
Capitalized Lease Obligations	'
	[13] Capitalized Lease Obligations
	The Company leases various assets under capital leases expiring in fiscal 2018 with interest rates ranging between 2% to 8% as follows:
		October 31
		2013		2012
	Medical Equipment	15,013		$	12,078
	Automobiles	10,581		8,711
	Totals	25,594		20,789
	Less: Accumulated Depreciation	13,125		6,776
	Net	12,469		$	14,013
	Depreciation expense on assets under capital leases was approximately $6,494, $3,792, and $1,418 for the years ended October 31, 2013, 2012 and 2011, respectively.
	Aggregate future minimum rentals under capital leases are:
	October 31,
	2014	$	5,622
	2015	4,630
	2016	3,727
	2017	2,192
	2018	660
	Thereafter	15
	Total	16,846
	Less Interest:	949
	Present Value of Minimum Lease Payments	$	15,897

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Oct. 31, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	[14] Commitments and Contingencies
	The Company leases various office and laboratory facilities and equipment under operating leases expiring from 2014 to 2019.  Several of these leases contain renewal options for one to five year periods.
	Total expense for property and equipment rental for the years ended October 31, 2013, 2012 and 2011 was $10,568, $8,787 and $8,010, respectively.  There were no contingent rental amounts due through October 31, 2013.
	Aggregate future minimum rental payments on non cancelable operating leases [exclusive of several month to month leases] are as follows:
	October 31,	Property($)	Equipment($)
	2014	8,671	344
	2015	2,333	223
	2016	1,422	87
	2017	558	—
	2018	558	—
	Thereafter	651	—
	Totals:	14,193	654
	The Company has entered into several purchase agreements for reagent supplies through October, 2018.  Minimum purchase commitments as of October 31, 2013 are as follows:
	October 31	Reagents ($)
	2014	12,505
	2015	11,938
	2016	10,854
	2017	6,559
	2018	3,700
	Thereafter	—
	Totals:	45,556
	Reagent supplies expensed under purchase agreements amount to $7,873, $13,338, and $8,379 for the years ended October 31, 2013, 2012 and 2011, respectively.

Litigation

Litigation	12 Months Ended
	Oct. 31, 2013
Litigation	'
Litigation	'
	[15] Litigation
	In the normal course of business, the Company is exposed to a number of asserted and unasserted potential claims.  In the opinion of management, the resolution of these matters will not have a material adverse effect on the Company’s financial position or results of operations.

Insurance

Insurance	12 Months Ended
	Oct. 31, 2013
Insurance	'
Insurance	'
	[16] Insurance
	The Company maintains professional liability insurance of $3,000 in the aggregate, with a per occurrence limit of $1,000.  In addition, the Company maintains excess commercial insurance of $5,000 per occurrence and $5,000 in aggregate over the primary limits.  In addition, the Company also maintains excess umbrella coverage of $15,000.

Significant_Risks_and_Uncertai

Significant Risks and Uncertainties	12 Months Ended
	Oct. 31, 2013
Significant Risks and Uncertainties	'
Significant Risks and Uncertainties	'
	[17] Significant Risks and Uncertainties
	[A] Concentrations of Credit Risk - Cash - At October 31, 2013 and 2012, the Company had approximately $14,720 and $21,260, respectively, in cash and certificate of deposit balances at financial institutions which were in excess of the federally insured limits.
	[B] Concentration of Credit Risk - Accounts Receivable - Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base.  The Company does have significant receivable balances with government payors and various insurance carriers.  Generally, the Company does not require collateral or other security to support customer receivables.  However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.
	A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to clinical laboratories.  Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company.  The Company is unable to predict, however, the extent to which such actions will be taken.

Acquisitions

Acquisitions	12 Months Ended
	Oct. 31, 2013
Acquisitions	'
Acquisitions	'
	[18] Acquisitions
	On April 27, 2012, the Company entered into an agreement pursuant to which the Company purchased preferred shares of IncellDx, Inc. (“IncellDx”), a Delaware corporation.  Information about IncellDx and the agreement may be found in the Current Report on Form 8-K the Company filed on May 1, 2012.
	As of October 31, 2013 the Company invested a total $6,000.
	On December 21, 2012, the Company entered into an agreement with Meridian Clinical Laboratory Corporation, a Florida corporation having its place of business in Miami, Florida (“Meridian”), pursuant to which the Company purchased all issued and outstanding common stock of Meridian for approximately $1,848 of which $250 is deferred for one year.
	On December 31, 2012, Bio-Reference Laboratories, Inc. (the “Company”) entered into an agreement with Florida Clinical Laboratory, Inc., a Florida corporation having its place of business in Melbourne, Florida (“FCL”), pursuant to which the Company purchased all issued and outstanding shares of capital stock of FCL for approximately $7,016, of which $1,000 is deferred for eighteen months assuming certain conditions, described, in the are met.
	The following table sets forth these final purchase allocations.
		($)
		FCL		MCL		Totals:
	Accounts Receivable	1,008		232		1,240
	Autos	137		48		185
	Medical Equipment	225		3		228
	Computer Equipment	21		—		21
	Leasehold Improvements	53		—		53
	Other Non-Current Assets	3		—		3
	Non-Compete Agreement	747		43		790
	Deposits	—		2		2
	Customer Relationships in Place	3,235		930		4,165
	Goodwill	1,905		673		2,578
	Accounts Payable	-118		-83		-201
	Long Term Debt (Auto-Loans)	-200		—		-200
	Short Term Acquisition Payable	-1,000		-250		-1,250
	Totals:	6,016		1,598		7,614
	On August 7, 2013 the Company purchased substantially all of the operating assets and certain of the operating liabilities of Hunter Laboratories, Inc., (“Hunter”) a California corporation having its principal place of business in Campbell, California.  The gross purchase price was $15,215 plus payroll adjustment of $111 totaling $15,326.  Of that amount $3,000 was deferred to cover anticipated pre closing liabilities.
	On August 20, 2013 the Company through its subsidiary GeneDx, Inc.,  purchased the entire membership interest in Edge BioServ, LLC, (“Edge Bio”) a Delaware limited liability company having its place of business in Gaithersburg, Maryland.  The gross purchase price was approximately $2,502.  Of that $375 was deferred to cover anticipated pre closing liabilities.
	The following table sets forth these final purchase allocations.
		$
		Hunter		Edge Bio		Totals:
	Accounts Receivable	1,700		—		1,700
	Prepaid Expenses	421		70		491
	Inventory	369		—		369
	Autos	62		—		62
	Furniture and Fixtures	265		6		271
	Leasehold Improvements	—		714		714
	Medical Equipment	234		906		1,140
	Computer Equipment	376		574		950
	Non-Compete Agreement	1,255		926		2,181
	Customer Relationships in Place	3,852		3		3,855
	Goodwill	8,573		182		8,755
	Accounts Payable	(1,388	)	—		(1,388	)
	Accrued Payroll Benefits	(393	)	—		(393	)
	Notes Payable	—		(578	)	(578	)
	Capital Leases	—		(193	)	(193	)
	Deferred Acquisition Payable	(3,000	)	(375	)	(3,375	)
	Deferred Rent Payable	—		(108	)	(108	)
	Totals:	12,326		2,127		14,453

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
	Oct. 31, 2013
Fair Value of Financial Instruments	'
Fair Value of Financial Instruments	'
	[19] Fair Value of Financial Instruments
	For certain financial instruments, including cash and cash equivalents, trade receivables, trade  payables, and short-term debt, it was estimated that the carrying amount approximated fair value for the majority of these items because of their short maturities.  The fair value of the Company’s long-term debt is estimated based on the quoted market prices for similar issues or by discounting expected cash flows at the rates currently offered to the Company for debt of the same remaining maturities.
	Due to the non-interest bearing nature and unspecified payment terms, it was not practicable to estimate the fair value of amounts due from related parties [See also Note 7].

Health_Insurance_Plan

Health Insurance Plan	12 Months Ended
	Oct. 31, 2013
Health Insurance Plan	'
Health Insurance Plan	'
	[20] Health Insurance Plan
	The Company has a limited self-funded health insurance plan for its employees under which the Company pays the initial $150 of covered medical expenses per person each year.  The Company has a contract with an insurance carrier for any excess up to a maximum of $2,000 per person and $20,504 in the aggregate.  Health insurance premium expense for the years ended October 31, 2013, 2012 and 2011 amounted to approximately $6,797, $5,792 and $4,426, respectively.  Uninsured employee medical expenses incurred by the Company amounted to approximately $32,016, $25,994 and $19,408 for the years ended October 31, 2013, 2012 and 2011, respectively.  During fiscal years ended October 31, 2013, 2012 and 2011, employee contributions of $4,713, $4,124 and $3,593 offset the above health plan costs.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Oct. 31, 2013
Employee Benefit Plan	'
Employee Benefit Plan	'
	[21] Employee Benefit Plan
	The Company sponsors a 401(k) Profit-Sharing Plan [the “Plan”].  Employees become eligible for participation after attaining the age of eighteen and completing one year of service.  Participants may elect to contribute up to ten percent of their compensation, as defined in the Plan, to a maximum allowed by the Internal Revenue Service.  The Company may choose to make a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year, at a percentage determined each year by the Company. The Company elected to make a matching contribution which amounted to $1,358 for 2013, $1,106 for 2012, and $993 for 2011.  These amounts were charged to the Statement of Operations. The Employer contribution will be fully vested after the third year of service.

New_Authoritative_Accounting_P

New Authoritative Accounting Pronouncements	12 Months Ended
	Oct. 31, 2013
New Authoritative Accounting Pronouncements	'
New Authoritative Accounting Pronouncements	'
	[22] New Authoritative Accounting Pronouncements
	The Company adopted Accounting Standard Update (“ASU”) No. 2011-7: Health Care Entities (Topic 954) — Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities commencing with the current fiscal year, the first year such standard is required for the Company. The adoption of this update did not have a material impact on the Company’s financial statements.
	Although this update does not have a material impact on the Company’s financial statements as a whole, it requires that we adjust our presentation of our statement of operations along with prior periods presented in this report to maintain comparability. As the result of this change in presentation, our “Net Revenues”, “Gross Profit on Revenues” and our “General and Administrative Expenses” would change while our “Operating Income”, “Net Income” and “Earnings per Share” will remain the same. The presentation is adjusted for a portion of our “Bad Debt Expense” that is now reported in our Net Revenues as required under ASU No. 2011-7.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data	12 Months Ended
	Oct. 31, 2013
Selected Quarterly Financial Data	'
Selected Quarterly Financial Data	'
	[23] Selected Quarterly Financial Data [Unaudited]
									Audited
		Three Month Ended							Fiscal Year
		1/31/13		4/30/13		7/31/13	10/31/13		2013
	Net Revenues	161,256		176,452		185,427	192,219		715,355
	Gross Profit	70,922		80,676		85,660	85,282		322,539
	Net Income	8,665		11,338		14,701	11,120		45,825
	Net Income Per Common Share:
	Basic	0.31		0.41		0.53	0.4		1.65
	Diluted	0.31		0.41		0.53	0.4		1.65
	Weighted Average Common Shares Outstanding — Basic [in thousands]	27,716		27,698		27,672	27,677		27,691
	Weighted Average Common Shares Outstanding - Diluted [in thousands]	27,912		27,879		27,842	27,844		27,851
												Audited
		Three Month Ended										Fiscal Year
		1/31/12			4/30/12		7/31/12			10/31/12		2012
	Net Revenues	$	138,793		$	151,443	$	160,532		$	163,487	$	614,255
	Gross Profit	$	60,118		$	67,534	$	74,279		$	74,681	$	276,611
	Net Income	$	7,365		$	9,306	$	12,596		$	12,889	$	42,156
	Net Income Per Common Share:
	Basic	$	0.26		$	0.34	$	0.45		$	0.47	$	1.52
	Diluted	$	0.26		$	0.33	$	0.45		$	0.46	$	1.51
	Weighted Average Common Shares Outstanding — Basic [in thousands]	27,888			27,685		27,695			27,705		27,742
	Weighted Average Common Shares Outstanding - Diluted [in thousands]	28,041			27,878		27,888			27,906		27,921
												Audited
		Three Month Ended										Fiscal Year
		1/31/11			4/30/11		7/31/11			10/31/11		2011
	Net Revenues	$	114,129		$	129,465	$	137,802		$	140,684	$	522,081
	Gross Profit	$	49,276		$	57,447	$	63,206		$	64,300	$	234,229
	Net Income	$	7,985		$	7,817	$	10,081		$	10,476	$	36,359
	Net Income Per Common Share:
	Basic	$	0.29		$	0.28	$	0.36		$	0.37	$	1.3
	Diluted	$	0.28		$	0.28	$	0.36		$	0.37	$	1.29
	Weighted Average Common Shares Outstanding — Basic [in thousands]	27,884			27,920		27,941			27,949		27,971
	Weighted Average Common Shares Outstanding - Diluted [in thousands]	28,122			28,142		28,147			28,138		28,207

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Oct. 31, 2013
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	'
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	'
	BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES
	SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED OCTOBER 31, 2013, 2012 AND 2011
	[In Thousands]
		(b)	(c)	(d)		(e)
	(a)	Balance at the	Charged to Cost and	Deductions Charged to Valuation		Balance at the End
	Description	Beginning of a Period	Expenses	Allowance Accounts		of a Period
	Year Ended October 31, 2013
	Allowance for Doubtful Accounts	51,274	119,161	(81,174	)	89,261
	Contractual Credits/Discounts	267,921	2,748,510	(2,674,134	)	342,297
	Total Allowance	319,195	2,867,671	(2,755,308	)	431,558
	Year Ended October 31, 2012
	Allowance for Doubtful Accounts	45,220	89,396	(83,342	)	51,274
	Contractual Credits/Discounts	235,922	2,390,770	(2,358,771	)	267,921
	Total Allowance	281,142	2,480,166	(2,442,113	)	319,195
	Year Ended October 31, 2011
	Allowance for Doubtful Accounts	34,904	75,079	(64,763	)	45,220
	Contractual Credits/Discounts	186,372	1,926,164	(1,876,614	)	235,922
	Total Allowance	221,276	2,001,243	(1,941,377	)	281,142

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2013
Summary of Significant Accounting Policies	'
Principles of Consolidation	'
	Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents - Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased.  The Company had $17,952 and $25,143 in cash and cash equivalents at October 31, 2013 and 2012, respectively.
Inventory	'
	Inventory - Inventory is stated at the lower of cost [determined on a first-in, first-out basis] or market.  Inventory consists of purchased laboratory supplies, which is used in our various testing laboratories.
Property and Equipment	'
	Property and Equipment - Property and equipment are carried at cost.  Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets, which generally range from 2 to 15 years.  Leasehold improvements are amortized over the life of the lease or improvement, which is typically five years.
	The statements of operations reflect depreciation expense related to property and equipment of $18,745, $16,082 and $13,684 for the years ended October 31, 2013, 2012 and 2011, respectively.
	On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in general and administrative expenses.  Repairs and maintenance are charged to expense when incurred.
Goodwill	'
	Goodwill - Effective November 1, 2011, the Company adopted revised Financial Accounting Standards Board (“FASB”)  rules promulgated under Accounting Standards Update (“ASU”) No. 2011-08 issued on September 15, 2011, Intangibles—Goodwill and Other (Topic 350) Testing Goodwill for Impairment. Under these simplified goodwill impairment testing rules the Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.  Under ASU No. 2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit’s carrying value is greater than its fair value based on an assessment of events and circumstances. The “more likely than not” threshold is when there is a likelihood of more than 50% that a reporting unit’s carrying value is greater than its fair value.  No impairment loss was recognized in the years ended October 31, 2013, 2012 and 2011.
	The balance sheet reflects prior Goodwill accumulated amortization of $2,401 as of October 31, 2013 and 2012, respectively.
Other Intangible Assets	'
	Other Intangible Assets - Intangible assets are amortized using the straight-line method.  The estimated useful life of costs capitalized is evaluated for each specific project when completed, at which time such costs begin to be amortized. The statements of operations reflect amortization expense related to intangible assets of $994, $581, and $1,322 for the years ended October 31, 2013, 2012 and 2011, respectively.  The balance sheet reflects accumulated amortization of $8,846, and $7,852 as of October 31, 2013, and 2012, respectively. During the 2013 and 2012 fiscal years, the Company did not write off any intangible assets.
New Accounting pronouncements	'
	New Accounting pronouncements
	Certain prior year amounts have been reclassified to conform to the current year presentation. The Company adopted Accounting Standard Update (“ASU”) No. 2011-7: Health Care Entities (Topic 954) — Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities commencing with the current fiscal year, the first year such standard is required for the Company. The adoption of this update did not have a material impact on the Company’s financial statements.
	Although this update does not have a material impact on the Company’s financial statements as a whole, it requires that we adjust our presentation of our statement of operations along with prior periods presented in this report to maintain comparability. As the result of this change in presentation, our “Net Revenues”, “Gross Profit on Revenues” and our “General and Administrative Expenses” would change while our “Operating Income”, “Net Income” and “Earnings per Share” will remain the same. The presentation is adjusted for a portion of our “Bad Debt Expense” that is now reported in our Net Revenues as required under ASU No. 2011-7.
Accounting for Revenue	'
	Accounting for Revenue
	Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.
	Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.  The majority of services provided by Bio-Reference Laboratories, Inc. (“BRLI”) are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburses BRLI directly.  In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends This process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed. The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.
		($)
		Year Ended
		October 31,
		2013		2012		2011
	Gross Service Revenues	3,524,108		3,052,431		2,482,349
	Contractual Adjustments and Discounts:
	Medicare/Medicaid Portion	354,638		320,697		293,874
	All Other Third Party Payors*	2,393,872		2,070,073		1,629,833
	Total Contractual Adjustments and Discounts	2,748,510		2,390,770		1,923,707
	Service Revenues Net of Contractual Adjustments and Discounts	775,598		661,661		558,642
	Patient Service Revenue Provision for Bad Debts**	60,244		47,406		36,561
	Net Revenues	715,354		614,255		522,081
	Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue.	79.7	%	79.9	%	79	%
	* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.
	** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.
	When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience. The remaining bad debt expense is presented as part of operating expenses. The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.  BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.
Accounting for Contractual Credits and Doubtful Accounts	'
	Accounting for Contractual Credits and Doubtful Accounts
	It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:
		($)
		October 31,		October 31,
		2013		2012
	Contractual Credits/Discounts	342,297		267,921
	Doubtful Accounts	89,261		51,274
	Total Allowance	431,558		319,195
Current Income Taxes	'
	Current Income Taxes — The Company recognizes interest and penalties on settlement of tax liabilities in its income from operations.  For the fiscal years 2011 through 2013, no material amounts for interest and penalties have been recorded.
Deferred Income Taxes	'
	Deferred Income Taxes - Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.
	The Company adopted GAAP guidance with respect to uncertain tax positions when it became effective.  Under these rules the Company may recognize the tax benefit from an uncertain tax position only if it meets the more-likely-than-not criteria (over 50% likelihood) of being realized on an examination by taxing authorities.  For the years ended October 31, 2011 through October 31, 2013 the Company had no material uncertain tax positions to report.
Earnings Per Share	'
	Earnings Per Share - Basic earnings per share [“EPS”] reflects the amount of income attributable to each share of common stock based on average common shares outstanding during the period.  Diluted EPS reflects Basic EPS while giving effect to all potential dilutive common shares that were outstanding during the period, such as common shares that could result from the exercise or conversion of securities into common stock.  The computation of Diluted EPS is calculated by using the treasury stock method, which assumes that any proceeds obtained from the exercise of such dilutive securities would be used to purchase common stock at the average market price of the common stock during the period.  This reduces the gross number of dilutive shares by the number of shares purchasable from the proceeds of the securities assumed to be exercised.  Securities whose conversion would have an anti-dilutive effect on EPS are not assumed converted.  Securities that could potentially dilute earnings in the future are disclosed in Note 10.
Use of Estimates	'
	Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets	'
	Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets — The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.  The Company reviews the recoverability of its long-lived assets on an annual basis.  Evaluation of possible impairment is based on the Company’s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.  No impairment loss was recognized in the fiscal years ended October 31, 2013, 2012 and 2011.
Advertising Costs	'
	Advertising Costs -Advertising costs are expensed when incurred.  Advertising costs amounted to approximately $3,200, $2,366 and $2,026 for the years ended October 31, 2013, 2012 and 2011, respectively.
Other Income	'
	Other Income — During the year the Company recorded a loss of $450on its investment in IncellDx.  The loss represents the Company’s share of IncellDX undistributed net loss under the equity method of accounting.  During the year ended October 31, 2013 the Company received a refund of $1,062 for its New York State clinical laboratory inspection fee that was included in other income.
Subsequent Events	'
	Subsequent Events — The management considered subsequent events through the date the financial statements are issued as defined in FASB Codification 855-10-50.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2013
Summary of Significant Accounting Policies	'
Schedule of adjustments made to gross service revenues to arrive at net revenues	'
		($)
		Year Ended
		October 31,
		2013		2012		2011
	Gross Service Revenues	3,524,108		3,052,431		2,482,349
	Contractual Adjustments and Discounts:
	Medicare/Medicaid Portion	354,638		320,697		293,874
	All Other Third Party Payors*	2,393,872		2,070,073		1,629,833
	Total Contractual Adjustments and Discounts	2,748,510		2,390,770		1,923,707
	Service Revenues Net of Contractual Adjustments and Discounts	775,598		661,661		558,642
	Patient Service Revenue Provision for Bad Debts**	60,244		47,406		36,561
	Net Revenues	715,354		614,255		522,081
	Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue.	79.7	%	79.9	%	79	%
	* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.
	** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.
Schedule of amounts for contractual credits and doubtful accounts	'
		($)
		October 31,		October 31,
		2013		2012
	Contractual Credits/Discounts	342,297		267,921
	Doubtful Accounts	89,261		51,274
	Total Allowance	431,558		319,195

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2013
Property and Equipment	'
Summary of property and equipment - at cost	'
		October 31
		2013		2012
	Medical Equipment	$	65,762	$	50,338
	Leasehold Improvements	27,974		19,768
	Furniture, Fixtures and Office & Computer Equipment	21,621		16,503
	Automobiles and Aircraft	18,242		16,092
	Sub Totals	133,599		102,701
	Less Accumulated Depreciation	67,950		52,261
	Totals — Net of Accumulated Depreciation	$	65,649	$	50,440

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Oct. 31, 2013
Intangible Assets	'
Schedule of information on intangible assets	'
	October 31, 2013
		Weighted-Average				Accumulated		Net of
								Accumulated
	Intangible Asset	Amortization Period		Cost		Amortization		Amortization
	Customer Lists	20		$	8,739	$	2,879	$	5,860
	Covenants Not-to-Compete	3		11,131		4,560		6,571
	Patents and Licenses	17		5,297		1,408		3,889
	Totals			$	25,166	$	8,847	$	16,320
	October 31, 2012
		Weighted-Average				Accumulated		Net of
								Accumulated
	Intangible Asset	Amortization Period		Cost		Amortization		Amortization
	Customer Lists	20		$	4,573	$	2,537	$	2,036
	Covenants Not-to-Compete	5		4,305		4,257		48
	Patents and Licenses	17		5,297		1,058		4,239
	Totals			$	14,175	$	7,852	$	6,323
Schedule of estimated amortization expense related to remaining intangible assets	'
	October 31,
	2014	$	1,917
	2015	1,852
	2016	1,540
	2017	1,063
	2018	946
	Thereafter	9,002
	Total	$	16,320

LongTerm_Debt_Bank_Tables

Long-Term Debt - Bank (Tables)	12 Months Ended
	Oct. 31, 2013
Long-Term Debt - Bank	'
Schedule of principal repayment for each of the five succeeding fiscal years and thereafter	'
	Year Ended
	October 31,
	2014	493
	2015	518
	2016	551
	2017	585
	2018	2,016
	Thereafter	—
	Totals	$	4,163

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2013
Income Taxes	'
Schedule of reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the Company's effective income tax rate	'
		October 31
		2013		2012		2011
	U.S. Federal Statutory Rate	35	%	35	%	35	%
	State and Local Taxes, Net of U.S. Federal Tax Benefit	11.2	%	8.87	%	9.87	%
	Permanent differences and Other	(2.78	)%	(0.44	)%	(0.94	)%
	Actual Rate	43.42	%	43.43	%	43.93	%
Schedule of provision for income taxes	'
		October 31
		2013			2012			2011
	Current:
	Federal	$	38,295		$	25,794		$	24,573
	State & Local	14,018			10,203			9,825
	Deferred:
	Federal	(10,803		)	(2,183		)	(4,223		)
	State and Local	(6,238		)	(1,454		)	(1,688		)
	Total Provision for Income Taxes	$	35,272		$	32,360		$	28,487
Schedule of net deferred tax asset [liability]	'
		October 31,
		2013			2012
	Deferred Tax Asset:
	Bad Debt Allowance	$	39,275		$	22,560
	Depreciation and amortization	1,815			1,963
	Accrued Expenses	3,141			2,667
	Deferred Tax Asset - Net	44,231			27,190
	Current Deferred Tax Asset - Net	42,154			24,912
	Long Term Deferred Tax Asset - Net	2,077			2,278
	Deferred Tax Asset — Net	44,231			$	27,190

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Oct. 31, 2013
Earnings Per Share	'
Schedule of computation of basic and diluted net earnings per common share	'
	The computation of basic and diluted net earnings per common share is as follows [in thousands, except per share data rounded]:
		For Years Ended October 31,
		2013		2012		2011
	Income Available to Common Stockholders	$	45,825	$	42,156	$	36,359
	Weighted Average Common Shares Outstanding	27,691		27,742		27,971
	Effect of Dilutive Securities:
	Warrants/Options	161		179		236
	Weighted Average Diluted Common Shares Outstanding	27,852		27,921		28,207
	Net Income Per Share - Basic	$	1.65	$	1.52	$	1.3
	Net Income Per Share - Diluted	$	1.65	$	1.51	$	1.29

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	12 Months Ended
	Oct. 31, 2013
Employee incentive stock options	'
Summary of outstanding options	'
							Weighted Average			Exercisable
							Shares	Remaining	Exercise	Shares	Exercise
	Exercise Price Range						Outstanding	Life	Price	Outstanding	Price
	$6.11	to		$6.11		Per Share	6	0.75	6.11	6	6.11
	$7.41	to		$7.67		Per Share	62	1.09	7.48	62	7.48
	$9.13	to		$9.13		Per Share	147	1	9.13	147	9.13
	$17.50	to		$17.50		Per Share	40	4.08	17.5	30	17.5
							255			245
2003 Plan	'
Employee incentive stock options	'
Summary of employee incentive stock option plan transactions	'
		2003 Plan
		Shares Under Options		Weighted Average
		[In Thousands]		Exercise Price Per Share
	Outstanding at October 31, 2010*	335		9.66
	Granted	—		—
	Expired	—		—
	Exercised	(40	)	8.67
	Outstanding at October 31, 2011*	295		9.8
	Granted	—		—
	Expired	(13	)	9.13
	Exercised	(23	)	8.52
	Outstanding at October 31, 2012*	259		$	9.95
	Granted	—		—
	Expired	(6	)	8.64
	Exercised	(4	)	7.25
	Outstanding at October 31, 2013*	249		10.02
	*Eligible for exercise at October 31, 2010 were 310 at a weighted average exercise price per share of $9.66
	*Eligible for exercise at October 31, 2011 were 275 at a weighted average exercise price per share of $9.80
	*Eligible for exercise at October 31, 2012 were 244 at a weighted average exercise price per share of $9.95
	*Eligible for exercise at October 31, 2013 were 239 at a weighted average exercise price per share of $9.97
2000 Plan	'
Employee incentive stock options	'
Summary of employee incentive stock option plan transactions	'
		2000 Plan
		Shares Under		Weighted
		Options		Average
		[In Thousands]		Exercise Price
				Per Share
	Outstanding and Eligible for Exercise at October 31, 2010	100		4.64
	Granted	—		—
	Expired	—		—
	Exercised	(40	)	3.82
	Outstanding and Eligible for Exercise at October 31, 2011	60		5.19
	Granted	—		—
	Expired	—		—
	Exercised	(8	)	3.39
	Outstanding and Eligible for Exercise at October 31, 2012	52		$	5.47
	Granted	—		—
	Expired	(2	)	3.6
	Exercised	(44	)	5.25
	Outstanding and Eligible for Exercise at October 31, 2013
		6		7.67

Employment_Contracts_and_Consu1

Employment Contracts and Consulting Agreements (Tables)	12 Months Ended
	Oct. 31, 2013
Employment Contracts and Consulting Agreements	'
Schedule of aggregate minimum commitment under employment contracts and agreements, excluding commissions or consumer price index increases	'
	October 31	Employees and
		Consultants
	2014	$	5,169
	2015	3,873
	2016	3,657
	2017	2,918
	2018	1,243
	Thereafter	—
	Total	$	16,860

Capitalized_Lease_Obligations_

Capitalized Lease Obligations (Tables)	12 Months Ended
	Oct. 31, 2013
Capitalized Lease Obligations	'
Schedule of assets under capital leases expiring in fiscal 2018	'
		October 31
		2013		2012
	Medical Equipment	15,013		$	12,078
	Automobiles	10,581		8,711
	Totals	25,594		20,789
	Less: Accumulated Depreciation	13,125		6,776
	Net	12,469		$	14,013
Schedule of aggregate future minimum rentals under capital leases	'
	October 31,
	2014	$	5,622
	2015	4,630
	2016	3,727
	2017	2,192
	2018	660
	Thereafter	15
	Total	16,846
	Less Interest:	949
	Present Value of Minimum Lease Payments	$	15,897

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Oct. 31, 2013
Commitments and Contingencies	'
Schedule of aggregate future minimum rental payments on non cancelable operating leases (exclusive of several month to month leases)	'
	October 31,	Property($)	Equipment($)
	2014	8,671	344
	2015	2,333	223
	2016	1,422	87
	2017	558	—
	2018	558	—
	Thereafter	651	—
	Totals:	14,193	654
Schedule of minimum purchase commitments	'
	October 31	Reagents ($)
	2014	12,505
	2015	11,938
	2016	10,854
	2017	6,559
	2018	3,700
	Thereafter	—
	Totals:	45,556

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Oct. 31, 2013
FCL and MCL	'
Acquisitions	'
Schedule of final purchase allocations	'
		($)
		FCL		MCL		Totals:
	Accounts Receivable	1,008		232		1,240
	Autos	137		48		185
	Medical Equipment	225		3		228
	Computer Equipment	21		—		21
	Leasehold Improvements	53		—		53
	Other Non-Current Assets	3		—		3
	Non-Compete Agreement	747		43		790
	Deposits	—		2		2
	Customer Relationships in Place	3,235		930		4,165
	Goodwill	1,905		673		2,578
	Accounts Payable	-118		-83		-201
	Long Term Debt (Auto-Loans)	-200		—		-200
	Short Term Acquisition Payable	-1,000		-250		-1,250
	Totals:	6,016		1,598		7,614
Hunter and Edge Bio	'
Acquisitions	'
Schedule of final purchase allocations	'
		$
		Hunter		Edge Bio		Totals:
	Accounts Receivable	1,700		—		1,700
	Prepaid Expenses	421		70		491
	Inventory	369		—		369
	Autos	62		—		62
	Furniture and Fixtures	265		6		271
	Leasehold Improvements	—		714		714
	Medical Equipment	234		906		1,140
	Computer Equipment	376		574		950
	Non-Compete Agreement	1,255		926		2,181
	Customer Relationships in Place	3,852		3		3,855
	Goodwill	8,573		182		8,755
	Accounts Payable	(1,388	)	—		(1,388	)
	Accrued Payroll Benefits	(393	)	—		(393	)
	Notes Payable	—		(578	)	(578	)
	Capital Leases	—		(193	)	(193	)
	Deferred Acquisition Payable	(3,000	)	(375	)	(3,375	)
	Deferred Rent Payable	—		(108	)	(108	)
	Totals:	12,326		2,127		14,453

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Oct. 31, 2013
Selected Quarterly Financial Data	'
Schedule of quarterly financial data	'
									Audited
		Three Month Ended							Fiscal Year
		1/31/13		4/30/13		7/31/13	10/31/13		2013
	Net Revenues	161,256		176,452		185,427	192,219		715,355
	Gross Profit	70,922		80,676		85,660	85,282		322,539
	Net Income	8,665		11,338		14,701	11,120		45,825
	Net Income Per Common Share:
	Basic	0.31		0.41		0.53	0.4		1.65
	Diluted	0.31		0.41		0.53	0.4		1.65
	Weighted Average Common Shares Outstanding — Basic [in thousands]	27,716		27,698		27,672	27,677		27,691
	Weighted Average Common Shares Outstanding - Diluted [in thousands]	27,912		27,879		27,842	27,844		27,851
												Audited
		Three Month Ended										Fiscal Year
		1/31/12			4/30/12		7/31/12			10/31/12		2012
	Net Revenues	$	138,793		$	151,443	$	160,532		$	163,487	$	614,255
	Gross Profit	$	60,118		$	67,534	$	74,279		$	74,681	$	276,611
	Net Income	$	7,365		$	9,306	$	12,596		$	12,889	$	42,156
	Net Income Per Common Share:
	Basic	$	0.26		$	0.34	$	0.45		$	0.47	$	1.52
	Diluted	$	0.26		$	0.33	$	0.45		$	0.46	$	1.51
	Weighted Average Common Shares Outstanding — Basic [in thousands]	27,888			27,685		27,695			27,705		27,742
	Weighted Average Common Shares Outstanding - Diluted [in thousands]	28,041			27,878		27,888			27,906		27,921
												Audited
		Three Month Ended										Fiscal Year
		1/31/11			4/30/11		7/31/11			10/31/11		2011
	Net Revenues	$	114,129		$	129,465	$	137,802		$	140,684	$	522,081
	Gross Profit	$	49,276		$	57,447	$	63,206		$	64,300	$	234,229
	Net Income	$	7,985		$	7,817	$	10,081		$	10,476	$	36,359
	Net Income Per Common Share:
	Basic	$	0.29		$	0.28	$	0.36		$	0.37	$	1.3
	Diluted	$	0.28		$	0.28	$	0.36		$	0.37	$	1.29
	Weighted Average Common Shares Outstanding — Basic [in thousands]	27,884			27,920		27,941			27,949		27,971
	Weighted Average Common Shares Outstanding - Diluted [in thousands]	28,122			28,142		28,147			28,138		28,207

Organization_and_Business_Deta

Organization and Business (Details)	12 Months Ended
	Oct. 31, 2013
	item
Organization and Business	'
Number of Reportable Segments	1
Laboratory testing business | Minimum	'
Organization and Business	'
Percentage of assets to consolidated assets	98.00%
Percentage of net revenue to consolidated net revenues	98.00%
Percentage of net income to consolidated net income	98.00%

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
Cash and Cash Equivalents	'	'	'	'
Cash and Cash Equivalents	$17,952	$25,143	$22,013	$17,779
Property and equipment	'	'	'	'
Depreciation expense	$18,745	$16,082	$13,684	'
Leasehold improvements	'	'	'	'
Property and equipment	'	'	'	'
Estimated useful lives	'5 years	'	'	'
Minimum	'	'	'	'
Property and equipment	'	'	'	'
Estimated useful lives	'2 years	'	'	'
Maximum	'	'	'	'
Property and equipment	'	'	'	'
Estimated useful lives	'15 years	'	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Goodwill	'	'	'
Impairment loss	$0	$0	$0
Goodwill accumulated amortization	2,401	2,401	'
Other Intangible Assets	'	'	'
Amortization expenses	994	581	1,322
Accumulated Amortization	$8,847	$7,852	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Oct. 31, 2013

Jul. 31, 2013

Apr. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Jul. 31, 2012

Apr. 30, 2012

Jan. 31, 2012

Oct. 31, 2011

Jul. 31, 2011

Apr. 30, 2011

Jan. 31, 2011

Oct. 31, 2013

Oct. 31, 2012

Oct. 31, 2011

Oct. 31, 2010

item

Accounting for Revenues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Service Revenues

'

'

'

'

'

'

'

'

'

'

'

'

$3,524,108

$3,052,431

$2,482,349

'

Contractual Adjustments and Discounts:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Medicare/Medicaid Portion

'

'

'

'

'

'

'

'

'

'

'

'

354,638

320,697

293,874

'

All Other Third Party Payors

'

'

'

'

'

'

'

'

'

'

'

'

2,393,872

2,070,073

1,629,833

'

Total Contractual Adjustments and Discounts

'

'

'

'

'

'

'

'

'

'

'

'

2,748,510

2,390,770

1,923,707

'

Service Revenues Net of Contractual Adjustments and Discounts

'

'

'

'

'

'

'

'

'

'

'

'

775,598

661,661

558,642

'

Patient Service Revenue Provision for Bad Debts

'

'

'

'

'

'

'

'

'

'

'

'

60,244

47,406

36,561

'

Net Revenues

192,219

185,427

176,452

161,256

163,487

160,532

151,443

138,793

140,684

137,802

129,465

114,129

715,354

614,255

522,081

'

Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue.

'

'

'

'

'

'

'

'

'

'

'

'

79.70%

79.90%

79.00%

'

Number of distinct payors included in all other third party and Direct

'

'

'

'

'

'

'

'

'

'

'

'

800

'

'

'

Allowances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Allowance

431,558

'

'

'

319,195

'

'

'

281,142

'

'

'

431,558

319,195

281,142

221,276

Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment loss

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

'

Contractual Credits/Discounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allowances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Allowance

342,297

'

'

'

267,921

'

'

'

235,922

'

'

'

342,297

267,921

235,922

186,372

Doubtful Accounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allowances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Allowance

$89,261

'

'

'

$51,274

'

'

'

$45,220

'

'

'

$89,261

$51,274

$45,220

$34,904

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Advertising Costs	'	'	'
Advertising Costs	$3,200	$2,366	$2,026
Equity method investment	'	'	'
Share of undistributed loss	450	323	'
Other Income	'	'	'
Amount of refund received related to New York State clinical laboratory inspection fee	1,062	'	'
IncellDx	'	'	'
Equity method investment	'	'	'
Share of undistributed loss	$450	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
In Thousands, unless otherwise specified
Property and equipment	'	'
PROPERTY AND EQUIPMENT - AT COST	$133,599	$102,701
Less Accumulated Depreciation	67,950	52,261
PROPERTY AND EQUIPMENT - NET	65,649	50,440
Medical Equipment	'	'
Property and equipment	'	'
PROPERTY AND EQUIPMENT - AT COST	65,762	50,338
Leasehold improvements	'	'
Property and equipment	'	'
PROPERTY AND EQUIPMENT - AT COST	27,974	19,768
Furniture, Fixtures and Office & Computer Equipment	'	'
Property and equipment	'	'
PROPERTY AND EQUIPMENT - AT COST	21,621	16,503
Automobiles and Aircraft	'	'
Property and equipment	'	'
PROPERTY AND EQUIPMENT - AT COST	$18,242	$16,092

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
Intangible assets	'	'
Cost	$25,166	$14,175
Accumulated Amortization	8,847	7,852
Net of Accumulated Amortization	16,320	6,323
Estimated amortization expense related to intangible assets	'	'
2014	1,917	'
2015	1,852	'
2016	1,540	'
2017	1,063	'
2018	946	'
Thereafter	9,002	'
Net of Accumulated Amortization	16,320	6,323
Customer Lists	'	'
Intangible assets	'	'
Weighted-Average Amortization Period	'20 years	'20 years
Cost	8,739	4,573
Accumulated Amortization	2,879	2,537
Net of Accumulated Amortization	5,860	2,036
Estimated amortization expense related to intangible assets	'	'
Net of Accumulated Amortization	5,860	2,036
Covenants Not-to-Compete	'	'
Intangible assets	'	'
Weighted-Average Amortization Period	'3 years	'5 years
Cost	11,131	4,305
Accumulated Amortization	4,560	4,257
Net of Accumulated Amortization	6,571	48
Estimated amortization expense related to intangible assets	'	'
Net of Accumulated Amortization	6,571	48
Patents and Licenses	'	'
Intangible assets	'	'
Weighted-Average Amortization Period	'17 years	'17 years
Cost	5,297	5,297
Accumulated Amortization	1,408	1,058
Net of Accumulated Amortization	3,889	4,239
Estimated amortization expense related to intangible assets	'	'
Net of Accumulated Amortization	$3,889	$4,239

Revolving_Note_Payable_Bank_De

Revolving Note Payable - Bank (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013
In Thousands, unless otherwise specified			Revolving note payable - bank	Revolving note payable - bank	Revolving note payable - bank	Revolving note payable - bank	Revolving note payable - bank	Revolving note payable - bank	Revolving note payable - bank
				Bank's base rate	Bank's base rate	Bank's base rate	Eurodollar rate	Eurodollar rate	Eurodollar rate
					Minimum	Maximum		Minimum	Maximum
Revolving note payable - Bank	'	'	'	'	'	'	'	'	'
Maximum amount of the credit line available pursuant to the loan agreement	'	'	$45,000	'	'	'	'	'	'
Maximum credit line available as percentage of accounts receivable	'	'	50.00%	'	'	'	'	'	'
Variable rate basis	'	'	'	'base rate	'	'	'Eurodollar rate	'	'
Percentage of additional interest	'	'	'	'	1.00%	4.00%	'	1.00%	4.00%
Variable rate of interest (as a percent)	'	'	'	3.50%	'	'	'	'	'
Amount of credit utilized	$26,139	$0	'	'	'	'	'	'	'

LongTerm_Debt_Bank_Details

Long-Term Debt - Bank (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2007	Oct. 31, 2007	Dec. 31, 2010	Oct. 31, 2013
		Term loan	Term loan	Term loan	Seven-year term note	Seven-year term note
				GeneDx, Inc.		item
Long-term debt	'	'	'	'	'	'
Debt instrument amount	'	'	$5,000,000	'	'	'
Amount used in connection with purchase of operating assets	'	'	'	5,000,000	'	'
Term of debt	'	'	'6 years	'	'7 years	'
Frequency of principal payments	'	'Monthly	'	'	'	'
Monthly principal payments	'	69,000	'	'	'	'
Debt instrument interest rate (as a percent)	'	6.85%	'	'	'	6.12%
Debt outstanding	4,163,000	'	'	'	'	4,163,000
Debt issued	'	'	'	'	5,408,000	'
Number of equal monthly installments	'	'	'	'	'	84
Monthly installment including principal and interest	'	'	'	'	'	61,000
Principal repayment for each of the five succeeding fiscal years and thereafter	'	'	'	'	'	'
2014	493,000	'	'	'	'	'
2015	518,000	'	'	'	'	'
2016	551,000	'	'	'	'	'
2017	585,000	'	'	'	'	'
2018	2,016,000	'	'	'	'	'
Totals	$4,163,000	'	'	'	'	$4,163,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the company's effective income tax rate	'	'	'
U.S. Federal Statutory Rate (as a percent)	35.00%	35.00%	35.00%
State and Local Taxes, Net of U.S. Federal Tax Benefit (as a percent)	11.20%	8.87%	9.87%
Permanent differences and Other (as a percent)	-2.78%	-0.44%	-0.94%
Actual Rate (as a percent)	43.42%	43.43%	43.93%
Current:	'	'	'
Federal	$38,295	$25,794	$24,573
State & Local	14,018	10,203	9,825
Deferred:	'	'	'
Federal	-10,803	-2,183	-4,223
State and Local	-6,238	-1,454	-1,688
Provision for Income Taxes	35,272	32,360	28,487
Net operating loss carry-forwards	0	0	0
Deferred Tax Asset:	'	'	'
Bad Debt Allowance	39,275	22,560	'
Depreciation and amortization	1,815	1,963	'
Accrued Expenses	3,141	2,667	'
Deferred Tax Asset - Net	44,231	27,190	'
Current Deferred Tax Asset - Net	42,154	24,912	'
Long Term Deferred Tax Asset - Net	2,077	2,278	'
Deferred Tax Asset - Net	44,231	27,190	'
Net deferred tax benefit	'	'	'
Net deferred tax benefit	17,041	3,638	5,911
Net benefit in allowance for bad debts	16,715	'	'
Benefit from depreciation and amortization	281	'	'
Benefit in certain accrued expenses	$607	'	'

Capital_Transactions_Details

Capital Transactions (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011	Dec. 19, 2013	Dec. 06, 2012	Nov. 11, 2011
	item
Capital Transactions	'	'	'	'	'	'
Preferred stock, shares authorized	1,666,667	1,666,667	'	'	'	'
Preferred stock, par value (in dollars per share)	$0.10	$0.10	'	'	'	'
Outstanding shares of preferred stock	0	0	'	'	'	'
Number of votes per share for holders of common stock	1	'	'	'	'	'
Number of shares of common stock authorized to be repurchased	'	'	'	2,000,000	714,550	1,000,000
Number of shares of common stock repurchased	81,600	285,450	'	'	'	'
Cost of shares of common stock repurchased	$2,030	$5,193	'	'	'	'
Number of shares of common stock issued for employment or consulting services	11,431	11,432	11,432	'	'	'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended												12 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Earnings Per Share	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Income Available to Common Stockholders (in dollars)	$11,120	$14,701	$11,338	$8,665	$12,889	$12,596	$9,306	$7,365	$10,476	$10,081	$7,817	$7,985	$45,825	$42,156	$36,359
Weighted Average Common Shares Outstanding (in shares)	27,677,000	27,672,000	27,698,000	27,716,000	27,705,000	27,695,000	27,685,000	27,888,000	27,949,000	27,941,000	27,920,000	27,884,000	27,690,677	27,742,257	27,971,100
Effect of Dilutive Securities: Warrants/Options (in shares)	'	'	'	'	'	'	'	'	'	'	'	'	161,000	179,000	236,000
Weighted Average Diluted Common Shares Outstanding (in shares)	27,844,000	27,842,000	27,879,000	27,912,000	27,906,000	27,888,000	27,878,000	28,041,000	28,138,000	28,147,000	28,142,000	28,122,000	27,851,720	27,920,920	28,207,358
Net Income Per Share - Basic (in dollars per share)	$0.40	$0.53	$0.41	$0.31	$0.47	$0.45	$0.34	$0.26	$0.37	$0.36	$0.28	$0.29	$1.65	$1.52	$1.30
Net Income Per Share - Diluted (in dollars per share)	$0.40	$0.53	$0.41	$0.31	$0.46	$0.45	$0.33	$0.26	$0.37	$0.36	$0.28	$0.28	$1.65	$1.51	$1.29

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
2003 Plan	'	'	'	'
Employee incentive stock options	'	'	'	'
Maximum aggregate shares of common stock authorized under the plan	1,600,000	'	'	'
Minimum specified percentage of outstanding common stock for the holder of which the exercise price must be at least 110% of fair market value	10.00%	'	'	'
Period within which options must be exercised by the optionee after termination of his employment due to retirement	'3 months	'	'	'
Period within which options must be exercised by the optionee after termination of employment due to disability or death	'1 year	'	'	'
Shares Under Options	'	'	'	'
Outstanding at the beginning of the period (in shares)	259,000	295,000	335,000	'
Granted (in shares)	0	0	0	'
Expired (in shares)	-6,000	-13,000	0	'
Exercised (in shares)	-4,000	-23,000	-40,000	'
Outstanding at the end of the period (in shares)	249,000	259,000	295,000	'
Weighted Average	'	'	'	'
Outstanding at the beginning of the period (in dollars per share)	$9.95	$9.80	$9.66	'
Expired (in dollars per share)	$8.64	$9.13	'	'
Exercised (in dollars per share)	$7.25	$8.52	$8.67	'
Outstanding at the end of the period (in dollars per share)	$10.02	$9.95	$9.80	'
Employee incentive stock option plan, additional disclosures	'	'	'	'
Outstanding options, eligible for exercise (in shares)	239,000	244,000	275,000	310,000
Outstanding options, eligible for exercise, weighted average exercise price (in dollars per share)	$9.97	$9.95	$9.80	$9.66
2003 Plan | Maximum	'	'	'	'
Employee incentive stock options	'	'	'	'
Option term	'10 years	'	'	'
Aggregate fair market value of the common stock with respect to which options are exercisable for the first time by the grantee (in dollars)	$100	'	'	'
Percentage of exercise price of option for which the Board (or a Stock Option Committee) in its sole discretion, cause the company to lend money or guaranty any obligation	50.00%	'	'	'
2003 Plan | Holder of 10% or more of the outstanding common stock	'	'	'	'
Employee incentive stock options	'	'	'	'
Exercise price as a percentage of fair value of common stock	110.00%	'	'	'
Option term	'5 years	'	'	'
2000 Plan	'	'	'	'
Employee incentive stock options	'	'	'	'
Maximum aggregate shares of common stock authorized under the plan	1,600,000	'	'	'
Exercise price as a percentage of fair value of common stock	100.00%	'	'	'
Minimum specified percentage of outstanding common stock for the holder of which the exercise price must be at least 110% of fair market value	10.00%	'	'	'
Shares Under Options	'	'	'	'
Outstanding at the beginning of the period (in shares)	52,000	60,000	100,000	'
Granted (in shares)	0	0	0	'
Expired (in shares)	-2,000	0	0	'
Exercised (in shares)	-44,000	-8,000	-40,000	'
Outstanding at the end of the period (in shares)	6,000	52,000	60,000	'
Weighted Average	'	'	'	'
Outstanding at the beginning of the period (in dollars per share)	$5.47	$5.19	$4.64	'
Expired (in dollars per share)	$3.60	'	'	'
Exercised (in dollars per share)	$5.25	$3.39	$3.82	'
Outstanding at the end of the period (in dollars per share)	$7.67	$5.47	$5.19	'
2000 Plan | Maximum	'	'	'	'
Employee incentive stock options	'	'	'	'
Option term	'10 years	'	'	'
2000 Plan | Holder of 10% or more of the outstanding common stock	'	'	'	'
Employee incentive stock options	'	'	'	'
Exercise price as a percentage of fair value of common stock	110.00%	'	'	'

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 2) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Employee Incentive Stock Options	'	'	'
Weighted Average, Shares Outstanding	255	'	'
Exercisable, Shares Outstanding	245	'	'
Compensation cost	'	'	'
Compensation cost recognized (in dollars)	$40	$40	$40
Compensation cost, related tax benefit (in dollars)	$0	$0	$0
$6.11 to $6.11	'	'	'
Employee Incentive Stock Options	'	'	'
Exercise price range, low end of range (in dollars per share)	$6.11	'	'
Exercise price range, high end of range (in dollars per share)	$6.11	'	'
Weighted Average, Shares Outstanding	6	'	'
Weighted Average, Remaining Life	'9 months	'	'
Weighted Average, Exercise Price (in dollars per share)	$6.11	'	'
Exercisable, Shares Outstanding	6	'	'
Exercisable, Exercise Price (in dollars per share)	$6.11	'	'
$7.41 to $7.67	'	'	'
Employee Incentive Stock Options	'	'	'
Exercise price range, low end of range (in dollars per share)	$7.41	'	'
Exercise price range, high end of range (in dollars per share)	$7.67	'	'
Weighted Average, Shares Outstanding	62	'	'
Weighted Average, Remaining Life	'1 year 1 month 2 days	'	'
Weighted Average, Exercise Price (in dollars per share)	$7.48	'	'
Exercisable, Shares Outstanding	62	'	'
Exercisable, Exercise Price (in dollars per share)	$7.48	'	'
$9.13 to $9.13	'	'	'
Employee Incentive Stock Options	'	'	'
Exercise price range, low end of range (in dollars per share)	$9.13	'	'
Exercise price range, high end of range (in dollars per share)	$9.13	'	'
Weighted Average, Shares Outstanding	147	'	'
Weighted Average, Remaining Life	'1 year	'	'
Weighted Average, Exercise Price (in dollars per share)	$9.13	'	'
Exercisable, Shares Outstanding	147	'	'
Exercisable, Exercise Price (in dollars per share)	$9.13	'	'
$17.50 to $17.50	'	'	'
Employee Incentive Stock Options	'	'	'
Exercise price range, low end of range (in dollars per share)	$17.50	'	'
Exercise price range, high end of range (in dollars per share)	$17.50	'	'
Weighted Average, Shares Outstanding	40	'	'
Weighted Average, Remaining Life	'4 years 29 days	'	'
Weighted Average, Exercise Price (in dollars per share)	$17.50	'	'
Exercisable, Shares Outstanding	30	'	'
Exercisable, Exercise Price (in dollars per share)	$17.50	'	'

Employment_Contracts_and_Consu2

Employment Contracts and Consulting Agreements (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013
	item
Aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases	'
2014	$5,169
2015	3,873
2016	3,657
2017	2,918
2018	1,243
Total	16,860
Number of additional at-will employment and consulting agreements	70
Annual aggregate commitments under agreement	$33,555
Minimum	'
Aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases	'
Bonuses and commissions based on percentage of collected revenues (as a percent)	1.00%
Maximum	'
Aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases	'
Bonuses and commissions based on percentage of collected revenues (as a percent)	10.00%

Capitalized_Lease_Obligations_1

Capitalized Lease Obligations (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Assets under capital leases	'	'	'
Totals	$25,594	$20,789	'
Less: Accumulated Depreciation	13,125	6,776	'
Net	12,469	14,013	'
Depreciation expense on assets under capital leases	6,494	3,792	1,418
Future minimum rentals under capital leases	'	'	'
2014	5,622	'	'
2015	4,630	'	'
2016	3,727	'	'
2017	2,192	'	'
2018	660	'	'
Thereafter	15	'	'
Total	16,846	'	'
Less Interest	949	'	'
Total	15,897	'	'
Minimum	'	'	'
Assets under capital leases	'	'	'
Interest rate under capital leases	2.00%	'	'
Maximum	'	'	'
Assets under capital leases	'	'	'
Interest rate under capital leases	8.00%	'	'
Medical Equipment	'	'	'
Assets under capital leases	'	'	'
Totals	15,013	12,078	'
Automobiles	'	'	'
Assets under capital leases	'	'	'
Totals	$10,581	$8,711	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Operating Leases	'	'	'
Total rental expenses for property and equipment	$10,568	$8,787	$8,010
Contingent rental amounts	0	'	'
Minimum purchase commitments	'	'	'
2014	12,505	'	'
2015	11,938	'	'
2016	10,854	'	'
2017	6,559	'	'
2018	3,700	'	'
Totals	45,556	'	'
Regent supplies expenses	7,873	13,338	8,379
Property	'	'	'
Aggregate future minimum rental payments	'	'	'
2014	8,671	'	'
2015	2,333	'	'
2016	1,422	'	'
2017	558	'	'
2018	558	'	'
Thereafter	651	'	'
Totals	14,193	'	'
Medical Equipment	'	'	'
Aggregate future minimum rental payments	'	'	'
2014	344	'	'
2015	223	'	'
2016	87	'	'
Totals	$654	'	'
Minimum	'	'	'
Operating Leases	'	'	'
Period of renewal options	'1 year	'	'
Maximum	'	'	'
Operating Leases	'	'	'
Period of renewal options	'5 years	'	'

Insurance_Details

Insurance (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013
Insurance	'
Professional liability insurance coverage	$3,000
Professional liability insurance coverage per occurrence	1,000
Excess commercial insurance coverage per occurrence	5,000
Excess commercial insurance coverage over the primary limits	5,000
Excess umbrella coverage	$15,000

Significant_Risks_and_Uncertai1

Significant Risks and Uncertainties (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
In Thousands, unless otherwise specified
Significant Risks and Uncertainties	'	'
Cash and certificate of deposit balances at financial institutions in excess of the federally insured limits	$14,720	$21,260

Acquisitions_Details

Acquisitions (Details) (USD $)

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 21, 2012

Dec. 21, 2012

Dec. 21, 2012

Dec. 21, 2012

Dec. 21, 2012

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 20, 2013

Aug. 20, 2013

Aug. 20, 2013

Aug. 20, 2013

Aug. 20, 2013

Aug. 20, 2013

Aug. 20, 2013

Oct. 31, 2013

In Thousands, unless otherwise specified

FCL and MCL

FCL and MCL

FCL and MCL

FCL and MCL

FCL and MCL

FCL and MCL

FCL and MCL

FCL

FCL

FCL

FCL

FCL

FCL

FCL

MCL

MCL

MCL

MCL

MCL

Hunter and Edge Bio

Hunter and Edge Bio

Hunter and Edge Bio

Hunter and Edge Bio

Hunter and Edge Bio

Hunter and Edge Bio

Hunter and Edge Bio

Hunter and Edge Bio

Hunter

Hunter

Hunter

Hunter

Hunter

Hunter

Hunter

Edge Bio

Edge Bio

Edge Bio

Edge Bio

Edge Bio

Edge Bio

Edge Bio

IncellDx

Non-Compete Agreement

Customer Relationships in Place

Autos

Medical Equipment

Computer Equipment

Leasehold Improvements

Non-Compete Agreement

Customer Relationships in Place

Autos

Medical Equipment

Computer Equipment

Leasehold Improvements

Non-Compete Agreement

Customer Relationships in Place

Autos

Medical Equipment

Non-Compete Agreement

Customer Relationships in Place

Autos

Furniture and Fixtures

Medical Equipment

Computer Equipment

Leasehold Improvements

Non-Compete Agreement

Customer Relationships in Place

Autos

Furniture and Fixtures

Medical Equipment

Computer Equipment

Non-Compete Agreement

Customer Relationships in Place

Furniture and Fixtures

Medical Equipment

Computer Equipment

Leasehold Improvements

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,000

Purchase price of issued and outstanding common stock

'

'

'

'

'

'

'

7,016

'

'

'

'

'

'

1,848

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferral period

'

'

'

'

'

'

'

'18 months

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final purchase allocations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts Receivable

1,240

'

'

'

'

'

'

1,008

'

'

'

'

'

'

232

'

'

'

'

1,700

'

'

'

'

'

'

'

1,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid Expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

491

'

'

'

'

'

'

'

421

'

'

'

'

'

'

70

'

'

'

'

'

'

'

Inventory

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

369

'

'

'

'

'

'

'

369

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, plant and equipment

'

'

'

185

228

21

53

'

'

'

137

225

21

53

'

'

'

48

3

'

'

'

62

271

1,140

950

714

'

'

'

62

265

234

376

'

'

'

6

906

574

714

'

Other Non-Current Assets

3

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets

'

790

4,165

'

'

'

'

'

747

3,235

'

'

'

'

'

43

930

'

'

'

2,181

3,855

'

'

'

'

'

'

1,255

3,852

'

'

'

'

'

926

3

'

'

'

'

'

Deposits

2

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

2,578

'

'

'

'

'

'

1,905

'

'

'

'

'

'

673

'

'

'

'

8,755

'

'

'

'

'

'

'

8,573

'

'

'

'

'

'

182

'

'

'

'

'

'

'

Accounts Payable

-201

'

'

'

'

'

'

-118

'

'

'

'

'

'

-83

'

'

'

'

-1,388

'

'

'

'

'

'

'

-1,388

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Payroll Benefits

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-393

'

'

'

'

'

'

'

-393

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note payable and Long Term Debt (Auto-Loans)

-200

'

'

'

'

'

'

-200

'

'

'

'

'

'

'

'

'

'

'

-578

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-578

'

'

'

'

'

'

'

Capital Leases

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-193

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-193

'

'

'

'

'

'

'

Short Term / Deferred Acquisition Payable

-1,250

'

'

'

'

'

'

-1,000

'

'

'

'

'

'

-250

'

'

'

'

-3,375

'

'

'

'

'

'

'

-3,000

'

'

'

'

'

'

-375

'

'

'

'

'

'

'

Deferred Rent Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-108

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-108

'

'

'

'

'

'

'

Totals:

7,614

'

'

'

'

'

'

6,016

'

'

'

'

'

'

1,598

'

'

'

'

14,453

'

'

'

'

'

'

'

12,326

'

'

'

'

'

'

2,127

'

'

'

'

'

'

'

Additional information

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross purchase price before payroll adjustment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,215

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payroll adjustment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

111

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15,326

'

'

'

'

'

'

$2,502

'

'

'

'

'

'

'

Health_Insurance_Plan_Details

Health Insurance Plan (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Health Insurance Plan	'	'	'
Initial amount the entity pays for covered medical expenses per person each year	$150	'	'
Maximum amount per person, covered by the third party insurance carrier for any excess	2,000	'	'
Maximum amount in the aggregate, covered by the third party insurance carrier for any excess	20,504	'	'
Health insurance premium expenses	6,797	5,792	4,426
Uninsured employee medical expenses	32,016	25,994	19,408
Employee contributions for limited health insurance plan	$4,713	$4,124	$3,593

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Employee Benefit Plan	'	'	'
Age requirement for employees to participate in the Plan	'18 years	'	'
Requisite service period	'1 year	'	'
Contribution by participants (as a percent)	10.00%	'	'
Entity's contribution under the Plan	$1,358	$1,106	$993

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended												12 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Selected Quarterly Financial Data	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Net Revenues	$192,219	$185,427	$176,452	$161,256	$163,487	$160,532	$151,443	$138,793	$140,684	$137,802	$129,465	$114,129	$715,354	$614,255	$522,081
Gross Profit	85,282	85,660	80,676	70,922	74,681	74,279	67,534	60,118	64,300	63,206	57,447	49,276	322,539	276,611	234,228
Net Income	$11,120	$14,701	$11,338	$8,665	$12,889	$12,596	$9,306	$7,365	$10,476	$10,081	$7,817	$7,985	$45,825	$42,156	$36,359
Net Income Per Common Share:	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Basic (in dollars per share)	$0.40	$0.53	$0.41	$0.31	$0.47	$0.45	$0.34	$0.26	$0.37	$0.36	$0.28	$0.29	$1.65	$1.52	$1.30
Diluted (in dollars per share)	$0.40	$0.53	$0.41	$0.31	$0.46	$0.45	$0.33	$0.26	$0.37	$0.36	$0.28	$0.28	$1.65	$1.51	$1.29
Weighted Average Common Shares Outstanding - Basic (in shares)	27,677,000	27,672,000	27,698,000	27,716,000	27,705,000	27,695,000	27,685,000	27,888,000	27,949,000	27,941,000	27,920,000	27,884,000	27,690,677	27,742,257	27,971,100
Weighted Average Common Shares Outstanding - Diluted (in shares)	27,844,000	27,842,000	27,879,000	27,912,000	27,906,000	27,888,000	27,878,000	28,041,000	28,138,000	28,147,000	28,142,000	28,122,000	27,851,720	27,920,920	28,207,358

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Valuation and qualifying accounts	'	'	'
Balance at the Beginning of a Period	$319,195	$281,142	$221,276
Charged to Cost and Expenses	2,867,671	2,480,166	2,001,243
Deductions Charged to Valuation Allowance Accounts	-2,755,308	-2,442,113	-1,941,377
Balance at the End of a Period	431,558	319,195	281,142
Allowance for Doubtful Accounts	'	'	'
Valuation and qualifying accounts	'	'	'
Balance at the Beginning of a Period	51,274	45,220	34,904
Charged to Cost and Expenses	119,161	89,396	75,079
Deductions Charged to Valuation Allowance Accounts	-81,174	-83,342	-64,763
Balance at the End of a Period	89,261	51,274	45,220
Contractual Credits/Discounts	'	'	'
Valuation and qualifying accounts	'	'	'
Balance at the Beginning of a Period	267,921	235,922	186,372
Charged to Cost and Expenses	2,748,510	2,390,770	1,926,164
Deductions Charged to Valuation Allowance Accounts	-2,674,134	-2,358,771	-1,876,614
Balance at the End of a Period	$342,297	$267,921	$235,922